ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Anti-TNF Drugs"

  • Abstract Number: 0642 • ACR Convergence 2020

    COVID-19 Infection in Rheumatologic Patients on Treatment with Targeted Therapies

    Marta González Fernández1, Orlando Pompei fernández2, Joaquín María Belzunegui Otano3, Paula García Escudero1, Claudia Stoye2, Juan Ramón De Dios2, Belén Álvarez Rodríguez2, Elena Garmendia Sánchez1, Susana Gil2, Ana Ruibal-Escribano4, Margarida Vasques Rocha2, Francisco García Llorente5, César Antonio Egües6, Edurne Guerrero7 and Jaime Calvo-Alén2, 1Hospital Universitario Cruces, Barakaldo, Spain, 2Hospital Universitario Araba, Vitoria-Gasteiz, Pais Vasco, Spain, 3Rheumatology Service, Hospital Universitario Donostia. San Sebastián, Spain, San Sebastian, Spain, 4Hospital Alfredo Espinosa, Urduliz, Pais Vasco, Spain, 5Hospital Universitario de Galdakao, Galdakao, Pais Vasco, Spain, 6Hospital Universitario Donostia, Donostia-San Sebastián, Pais Vasco, Spain, 7Hospital Alto Deba, Arrasate, Pais Vasco, Spain

    Background/Purpose: SARS COV 2 pandemic has been an issue which has challenged the health care systems around the world. Rheumatology has been involved in two…
  • Abstract Number: 0897 • ACR Convergence 2020

    Temporal Achievement of Clinical Response and Inactive Disease Status in Patients with Axial Spondyloarthritis Treated with Etanercept

    Xenofon Baraliakos1, Annette Szumski2, Kenneth Kwok3 and Bonnie Vlahos4, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, 2Syneos Health, Princeton, 3Pfizer, New York, NY, 4Pfizer, Collegeville, PA

    Background/Purpose: Treatment with etanercept (ETN) is effective and well tolerated in patients with axial spondyloarthritis (AS), but the time frames within which patients tend to…
  • Abstract Number: 1399 • ACR Convergence 2020

    Differential Impacts of TNFa Inhibitors on the Expression of Th Cytokines

    Ching-Huang Ho1, Andrea Silva1 and I-Cheng Ho2, 1Brigham and Women's Hospital, Boston, MA, 2Birgham and Women's Hospital, Boston, MA

    Background/Purpose: Inhibition of TNFα has emerged as an effective therapeutic approach for many autoimmune/inflammatory diseases.While the efficacy and safety profile of the five FDA-approved TNFis…
  • Abstract Number: 0710 • ACR Convergence 2020

    Early Start of Biological Treatment in Juvenile Idiopathic Arthritis: Does a Therapeutic Window Exist in Real Life?

    Alina Lucica Boteanu1, Andrea Briones-Figueroa2, Laura Calvo-Sanz2, África Andreu Suárez2 and Antía García-Fernández2, 1PRINTO, Istituto Giannina Gaslini, Genova, Italy, 2Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain

    Background/Purpose: Data about when is the best moment to start BT in Juvenile Idiopathic Arthritis (JIA) patients and the impact of this prompt initiation are…
  • Abstract Number: 0909 • ACR Convergence 2020

    Residual Disease Activity in Psoriatic Arthritis Patients Treated with Secukinumab and Adalimumab Who Achieved Remission or Low Disease Activity: Results from a Phase 3b, Randomized, Double-blinded, Active-controlled, Head-to-head Study

    Iain McInnes1, Philip Mease2, Dafna Gladman3, Laura Coates4, Peter Nash5, Alexis Ogdie6, Frank Behrens7, Philippe Goupille8, Arthur Kavanaugh9, Ruvie Martin10, Erhard Quebe-Fehling11 and Corine Gaillez11, 1Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, 2Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 3Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 4University of Oxford, Oxford, United Kingdom, 5School of Medicine Griffith University, Brisbane, Queensland, Australia, 6University of Pennsylvania, Philadelphia, PA, 7CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, 8CHU Tours, department of rheumatology, Tours, France, 9Division of Rheumatology, Allergy, & Immunology, University of California San Diego Medical School, San Diego, CA, 10Novartis Pharmaceuticals Corporation, East Hanover, NJ, 11Novartis Pharma AG, Basel, Switzerland

    Background/Purpose: Recent EULAR recommendations propose that treatment of psoriatic arthritis (PsA) should seek remission (REM) or alternatively low disease activity (LDA) by regular disease activity…
  • Abstract Number: 1406 • ACR Convergence 2020

    LAG-3+ T Cells Are Diminished in Active Psoriatic Arthritis Patients and Their Restoration in Vitro Is Mediated by TNF Inhibitors

    Smadar Gertel1, Ari Polachek2, Victoria Furer3, David Levartovsky3 and Ori Elkayam4, 1Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel, 2Tel Aviv Sourasky Medical Center, Petah-Tikva, Israel, 3Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 4Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel

    Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with psoriasis. Aberrant T cell regulation has been implicated in the process of inflammation in…
  • Abstract Number: 0712 • ACR Convergence 2020

    Switching from Reference to Biosimilars Does Not Reduce Efficacy and Safety in Juvenile Idiopathic Arthritis

    Ilaria Maccora1, Gabriele Simonini2, Alessandra Bettiol3, Ilaria Pagnini4, Niccolò Lombardi5, Valerio Maniscalco6, Giada Crescioli5, Edoardo Marrani7, Roberto Bonaiuti5, Maria Vincenza Mastrolia8, Claudia Ravaldi9 and Alfredo Vannacci5, 1Paediatric Rheumatology Unit, Anna Meyer Children's University Hospital, School of Human Health Science, Florence, Italy, Florence, Italy, 2Rheumatology Unit, Meyer Children's University Hospital, Florence; NEUROFARBA Department, University of Florence, Italy, Florence, Italy, 32. Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy, Florence, 41. Rheumatology Unit, Anna Meyer Children’s Hospital and Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Paediatric, University of Florence, Florence, Italy, florence, Italy, 52. Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy., Florence, Italy, 61. Rheumatology Unit, Anna Meyer Children’s Hospital and Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Paediatric, University of Florence, Florence, Italy., florence, Italy, 7University of Florence, Firenze, Italy, 8Rheumatology Unit, Meyer Children's University Hospital, Firenze, Italy, Florence, Toscana, Italy, 93. Department of Health Sciences, University of Florence, Florence, Italy., Florence, Italy

    Background/Purpose: Limited data about the use of biosimilar are available in children with Juvenile Idiopathic Arthritis (JIA). To evaluate the long-term efficacy and safety of switching…
  • Abstract Number: 1045 • ACR Convergence 2020

    Biological therapy in atypical optic neuritis refractory to conventional treatment. A multicenter study with 19 patients.

    Inigo Gonzalez-Mazon1, Alba Herrero Morant2, Lara Sanchez-Bilbao2, David Martinez-Lopez3, Vanesa Calvo-Río4, Carmen Alvarez-Reguera2, Santos Castañeda5, Esther Francisca Vicente-Rabaneda6, Rosalia Demetrio-Pablo2, Ana Urruticoechea-Arana7, J. L. García-Serrano8, J. L. Callejas-Rubio8, Norberto Ortego8, José Luis Martín-Varillas9, Olga Maiz Alonso10, Ana Blanco11, Francisco Javier Narváez12, Susana Romero-Yuste13, Iñigo Rúa-Figueroa14, Paula Estrada15, Julio Sanchez16, Miguel Ángel González-Gay17 and Ricardo Blanco2, 1Hospital Universitario Marques de Valdecilla, Bezana, Spain, 2Hospital Universitario Marques de Valdecilla, Santander, Spain, 3Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, 4H.U. Marques de Valdecilla, Santander, Spain, 5Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, 6Hospital Universitario de la Princesa, IIS-Princesa, UAM, Madrid, Madrid, Spain, 7HOSPITAL CAN MISSES EIVISSA, Ibiza, Spain, 8Hospital Universitario San Cecilio, Granada, Spain, 9Hospital Sierrallana, Torrelavega, Spain, 10Hospital Universitario Donostia, San Sebastian, Pais Vasco, Spain, 11Hospital Universitario Donostia, San Sebastian, Spain, 12Hospital Bellvitge, BARCELONA, Spain, 13H Pontevedra, Coruna, Spain, 14Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain, 15Hospital Universitario de Bellvitge, Barcelona, Spain, 16Hospital 12 Octubre, Madrid, Spain, 17Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

    Background/Purpose: Optic Neuritis (ON) is an inflammation of the optic nerve. Its most common presentation is demyelinating typical ON. Atypical ON is rare, severe, non-demyelinating…
  • Abstract Number: 1544 • ACR Convergence 2020

    Tc99m Tilmanocept Imaging Is an Early Predictor of Clinical Response in Rheumatoid Arthritis Patients Beginning New Anti-TNFα Therapy

    Mara Leach1, David Ralph1, Beth Potter1, Bonnie Abbruzzese1, Rachael Hershey1, Jessica Fitzpatrick1, Katherine Repp1, Haya Shakhtra1, Madison Palmer1, Nicole Korczak1, Audrey Villarosa1, Michael Blue1, Martin Jacobs2, Yelliann Ruis3, Debbie Foley4, Alan Kivitz5 and Michael Rosol1, 1Navidea Biopharmaceuticals, Dublin, 2Kettering Medical Center, Kettering, 3Innovation Medical Research Center, Palmetto Bay, 4Premier Rheumatology of Oklahoma, Tulsa, 5Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA

    Background/Purpose: Rheumatoid Arthritis (RA) is a serious and potentially debilitating disease, but low disease activity and even clinical remission can be obtained if an effective…
  • Abstract Number: 0011 • ACR Convergence 2020

    Patients Receiving Cytokine Inhibitors Have Low Prevalence of SARS-CoV-2 Infection

    David Simon1, Koray Tascilar1, Gerhard Krönke2, Arnd Kleyer1, Mario Zaiss3, Franz Heppt4, Christine Meder4, Raja Atreya5, Entcho Klenske5, Peter Dietrich5, Abdullah Abdullah5, Thorsten Kliem5, Giulia Corte6, Harriet Morf3, Moritz Leppkes5, Andreas Kremer5, Andreas Ramming3, Milena Pachowsky7, Florian Schuch8, Monika Ronneberger9, Stefan Kleinert10, Clara Maier11, Axel Hueber12, Karin Manger13, Bernhard Manger3, Carola Berking4, Matthias Tenbusch11, Klaus Überla11, Michael Sticherling3, Markus Neurath5 and Georg Schett14, 1Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, 2Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Georgia, 3Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, 4Department of Dermatology, FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, 5Department of Internal Medicine 1, FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, 6Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Gibraltar, 7Department of Orthopedic and Trauma Surgery, FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, 8Rheumatology Clinical Practice Erlangen, Erlangen, Ghana, 9Rheumatology Clinical Practice Erlangen, Erlangen, Germany, 10Rheumatology-Nephrology Practice, Erlangen, Germany, 11Institute of Clinical and Molecular Virology, FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, 12Sozialstiftung Bamberg, Sektion Rheumatologie, Bamberg, Germany, 13Rheumatology Practice Bamberg, Bamberg, Germany, 14Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany

    Background/Purpose: Therapeutic interventions for Immune-mediated inflammatory diseases (IMIDs) target cytokines, such as TNF-a, IL-6, IL-17 and IL-23, which are involved in the physiological and pathological…
  • Abstract Number: 0716 • ACR Convergence 2020

    Variations in Adalimumab and Etanercept Dosing in Juvenile Idiopathic Arthritis and Their Effect on Treatment Outcome: A Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry Study

    Ruud Verstegen1, Peter Shrader2, Stephen Balevic3, Timothy Beukelman4, Colleen Correll5, Anne Dennos6, Thomas Phillips2 and Brian Feldman1, 1The Hospital for Sick Children, Toronto, ON, Canada, 2Duke University, Durham, 3Duke University Medical Center, Durham, 4University of Alabama at Birmingham, Birmingham, AL, 5University of Minnesota, Minneapolis, MN, 6Duke University, Durham, NC

    Background/Purpose: Different dosing strategies of adalimumab and etanercept have been used over the past decade in the treatment of juvenile idiopathic arthritis (JIA). With regards…
  • Abstract Number: 1054 • ACR Convergence 2020

    Treatment with Certolizumab Pegol in Refractory Uveitis Secondary to Inmune-Mediated Inflammatory Diseases. Multicenter Study of 39 Patients

    José Luis Martín-Varillas1, Vanesa Calvo-Río2, Lara Sanchez-Bilbao2, Inigo Gonzalez-Mazon3, Ignacio Torre4, Alvaro García Martos5, Amalia Sánchez Andrade6, Angel García Aparicio7, Juan Ramón De dios8, Ana Urriticoechea9, Olga Maiz Alonso10, Raul Veroz11, Andrea García Valle12, Sergio Rodriguez Montero13, Roberto Miguelez14, Vega Jovani15, Marisa Hernandez Garfella16, Arantxa Conesa17, Olga Martinez Gonzalez18, Paula Rubio Muñoz19, Eva Peña Sainz-Pardo20, Miguel Ángel González-Gay21 and Ricardo Blanco2, 1Hospital Sierrallana, Torrelavega, Spain, 2Hospital Universitario Marques de Valdecilla, Santander, Spain, 3Hospital Universitario Marques de Valdecilla, Bezana, Spain, 4Hospital Basurto, Bilbao, Spain, 5Hospital del Tajo, Madrid, Spain, 6H. Lucus Augusti, Lugo, Spain, 7H. Mostoles, Madrid, Spain, 8H. Alava, Alava, Spain, 9Can Misses, Ibiza, Spain, 10Hospital Universitario Donostia, San Sebastian, Pais Vasco, Spain, 11H. Mérida, Mérida, Spain, 12H. Palencia, Palencia, Spain, 13H. Virgen de Valme, Sevilla, Spain, 14Toledo, Toledo, Spain, 15H. Alicante, Alicante, Spain, 16H. Valencia, Valencia, Spain, 17H. Castellón, Castellón, 18H. Salamanca, Salamanca, 19H. Esperit Sant, Barcelona, Spain, 20H. 12 de Octubre, Madrid, Spain, 21Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

    Background/Purpose: Infliximab and adalimumab therapy has significantly improved the prognosis of patients with non-infectious refractory uveitis. However, there is not enough evidence for the use…
  • Abstract Number: 1605 • ACR Convergence 2020

    Knowledge of Biosimilars and Perceptions of Biosimilar Naming Conventions in Clinical Practice

    Criswell Lavery1, Marianna Olave2, Charles Leonard1, Vincent Lo Re1, Jonathan Kay3 and Joshua Baker1, 1University of Pennsylvania, Philadelphia, PA, 2Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, 3University of Massachusetts Medical School, Worcester, MA

    Background/Purpose: The market introduction of biosimilars has generated the need for novel biologic naming conventions, in part to support pharmacovigilance. We evaluated the familiarity of…
  • Abstract Number: 0038 • ACR Convergence 2020

    Protein Biomarkers May Differentiate Responders and Non-Responders to Adalimumab, a Tumour Necrosis Factor Inhibitor, in Ankylosing Spondylitis Patients – The Bioefficacy SpA Study

    Ana Fernandes1, Atlas Mashayekhi Sardoo2, Miguel Bernardes3, Patrícia Pinto4, Helena Santos5, João Lagoas Gomes6, José Tavares-Costa7, José A. P. da Silva8, João Madruga-Dias9, Alexandra Bernardo10, Jean-Charles Gaillard11, Lúcia Domingues12, Sara Maia12, Jean Armengaud11, Jaime C. Branco13, Ana Varela Coelho14 and Fernando Pimentel-Santos15, 11.Instituto de Tecnologia Química e Biológica, Universidade NOVA de Lisboa; 2.Universidade de Trás-os-Montes e Alto Douro, Vila Real, Portugal, Oeiras, Portugal, 23. CEDOC, NOVA Medical School, Faculdade de Ciências Médicas da Universidade NOVA de Lisboa, Lisboa, Portugal, Lisbon, Portugal, 34.Centro Hospitalar de S. João (Rheumatology Department) , Porto, Portugal, Porto, Portugal, 45. Centro Hospitalar de Vila Nova de Gaia/Espinho (Rheumatology Department), Vila Nova de Gaia, Portugal, Vila Nova de Gaia, Portugal, 56.Instituto Português de Reumatologia (Rheumatology Department), Lisboa, Portugal, Lisboa, Portugal, 67.Hospital Egas Moniz (CHLO) (Rheumatology Department), Lisboa, Portugal, Lisboa, Portugal, 78.Unidade Local de Saúde do Alto Minho (Rheumatology Department), Ponte de Lima, Portugal, Ponte de Lima, Portugal, 89.Centro Hospitalar e Universitário Coimbra (Rheumatology Department), Coimbra, Portugal, Coimbra, Portugal, 910.Centro Hospital Médio Tejo (Rheumatology Department), Torres Novas, Portugal, Dublin, Ireland, 105.Centro Hospitalar de Vila Nova de Gaia/Espinho (Rheumatology Department), Vila Nova de Gaia, Portugal, Vila Nova de Gaia, Portugal, 1111.Centre d énergie atomique (Laboratoire Innovations technologiques pour la Détection et le Diagnostic (Li2D), Service de Pharmacologie et Immunoanalyse (SPI)), Avignon, France, Avignon, France, 123.CEDOC, NOVA Medical School. Faculdade de Ciências Médicas da Universidade NOVA de Lisboa, Lisboa, Portugal, Lisboa, Portugal, 133.CEDOC, NOVA Medical School, Faculdade de Ciências Médicas da Universidade NOVA de Lisboa, Lisboa, Portugal; 7.Hospital Egas Moniz (CHLO) (Rheumatology Department), Lisboa, Portugal, Lisboa, Portugal, 141.Instituto de Tecnologia Química e Biológica, Universidade NOVA de Lisboa, Oeiras, Portugal, Oeiras, Portugal, 153.CEDOC, NOVA Medical School, Faculdade de Ciências Médicas da Universidade NOVA de Lisboa, Lisboa, Portugal; 7.Hospital Egas Moniz (CHLO) (Rheumatology Department), Lisboa, Portugal, Lisbon, Portugal

    Background/Purpose: Axial Spondyloarthritis (AS) is amongst the most common forms of inflammatory arthritis. Widely used in the treatment of axSpA, adalimumab is an engineered antibody…
  • Abstract Number: 0717 • ACR Convergence 2020

    Predictors of Clinical Remission in Children with Extended Oligoarticular Arthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis Treated with Etanercept in the CLIPPER Studies

    Jelena Vojinovic1, Vyacheslav Chasnyk1, Joke Dehoorne1, Violeta Panaviene1, Jonathan Akikusa2, Tadej Avcin1, Jeffrey Chaitow1, Bernard Lauwerys1, Jordi Antón1, Inmaculada Penades1, Berit Flato1, Alina Boteanu3, Hans-Iko Huppertz1, Juan Jaller1, Daniela Graham4, Cecilia Borlenghi5, Bonnie Vlahos6, Chuanbo Zang6 and Nicolino Ruperto2, 1Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, 2PRINTO, Istituto Giannina Gaslini, Genova, Italy, 3Hospital Universitario Ramón y Cajal, Madrid, Spain, 4Pfizer, Groton, PA, 5Pfizer, New York, NY, 6Pfizer, Collegeville, PA

    Background/Purpose: CLIPPER is an ongoing, 8-year, phase 3b, multicenter, open-label study of the safety and efficacy of etanercept in the treatment of juvenile idiopathic arthritis…
  • « Previous Page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology